Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of ABSK043 plus golarexib in KRAS G12C-mutant advanced or metastatic non-small cell lung cancer
CTR20253562Phase 2Active
- Sponsor
- Abbisko Therapeutics
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lumipodlin, glecirasib in non-small cell lung cancer (NSCLC), sponsored by Abbisko Therapeutics. Started Sep 2025; status: active.
02
Drugs
lumipodlinglecirasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253562.